Hutchmed (China) (00013) rose more than 5%, and at the time of publication, rose 5.41%, to 31.2 Hong Kong dollars, with a turnover of 44.2823 million Hong Kong dollars.
According to the Zhicheng Financial APP, Hutchmed (China) (00013) rose more than 5%, and at the time of publication, rose 5.41%, to 31.2 Hong Kong dollars, with a turnover of 44.2823 million Hong Kong dollars.
On July 9, Hutchmed (China) held the 2024 R&D Day exchange event. The company's management focused on sharing the clinical data and market value of candidate innovative pipelines, including clinical data and advantage analysis of surufatinib in autoimmune diseases, the treatment potential of savolitinib in pancreatic cancer, early data analysis of HMPL-306 for the treatment of acute myeloid leukemia, and phase III clinical study design.
Northeast Securities pointed out that the company's recent R&D progress has been rapid, with multiple products simultaneously exerting efforts, demonstrating excellent clinical data and competitive landscape, and constantly promoting global product globalization. It is expected to continue to catalyze the fundamental value of the company. In addition, the company has rich pipeline reserves and a broad product market space, constantly achieving overseas release.